FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compound, represented by general formula 
or its pharmaceutically acceptable salt, in which R1 and R2 independently represent hydrogen atom, C1-C6alkylsulphonyl group, which includes cyclopropylsulphonyl group, or C1-C6alkoxy- C1-C6alkylsulphonyl group, and A is selected from group which includes: thiazolyl group, 1,2,4-thiadiazolyl group, pyrazolyl group, pyridyl group, pyrazinyl group, isooxazolyl group, benzothiazolyl group and thiazolo[5,4-b]pyridyl group, and A can be mono-substituted by substituent, selected from group, which includes halogen atom; C1-C6alkyl groups, optionally substituted with halogen atom or hydroxyl group; C1-C6alkoxyl groups, optionally substituted with halogen atom or hydroxyl group; C1-C3alkoxy-C1-C2alkoxyl groups; C1-C3alkoxycarbonyl-C1-C2alkoxyl groups; C1-C6alkylsulphanyl groups; C1-C6amino-alkylsulphanyl group, optionally substituted with C1-C3alkyl group; C1-C6alkylsulphanyl-C1-C6alcoxyl groups; phenyl group; 1,3-dipxolane, substituted with two C1-C6alkyl groups; piperazinesulphonyl is substituted with methyl group; 1,3-dioxolanemethyl, substituted with two methyl groups; piperazinemethyl, substituted with methyl group; tetrahydropyranyloxy-C1-C3alkoxy group; aminosulphonyl groups, optionally substituted with C1-C3alkyl group; C1-C6 hydroxyalkylsulphanyl groups; -(O)(CH2)C(O)O-C1-C6alkyl group; -C(O)O-C1-C6 alkyl group; as well as groups, represented by general formula -(CH2)mP(O)R4R5 (where R4 and R5 independently represent C1-C3alkoxyl group; m is integer number from 0 to 1). Compound of formula (1) is intended, as active ingredient, for production of pharmaceutical composition, which has effect for activation of glucokinase (GK) or hypoglycaemic action. Invention also relates to intermediate compounds, represented by formula 
in which R1 and R2 independently represent hydrogen atom, C1-C6alkylsulphonyl group, which includes cyclopropylsulphonyl group, or C1-C6alkoxy-C1-C6alkylsulphonyl group.
EFFECT: acrylamide compounds as glucokinase activator for treatment of diabetes.
21 cl, 38 tbl, 55 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES AND RESPIRATORY WAYS DISEASES | 2001 |
|
RU2265011C2 |
| COMPOUNDS USEFUL AS TRPM8 MODULATORS | 2011 |
|
RU2608109C2 |
| AMINO ACID DERIVATIVES | 1994 |
|
RU2127261C1 |
| SUBSTITUTED AMINO SIX-MEMBER SATURATED HETEROALICYCLES AS LONG-ACTING DPP-IV INHIBITORS | 2016 |
|
RU2720488C2 |
| PYRROLE DERIVATIVES AS MEDICINAL SUBSTANCES | 2005 |
|
RU2470916C2 |
| ELECTROCHEMICAL METHOD FOR OBTAINING TETRAHYDROQUINOLINE DERIVATIVES, THEIR USE AS FUNGICIDAL AGENTS AND FUNGICIDAL COMPOSITIONS BASED ON THEM | 2022 |
|
RU2784323C1 |
| DERIVATIVES OF 2-IMINOPYRROLIDINE | 2002 |
|
RU2270192C2 |
| PYRROLO[2,1-f][1,2,4]TRIAZINE COMPOUND, METHOD FOR PRODUCTION AND USE THEREOF | 2013 |
|
RU2589053C1 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| NOVEL PIRIDAZONES AND TRIAZINONES FOR TREATMENT AND PREVENTING OF HEPATITIS B VIRUS INFECTION | 2015 |
|
RU2664329C1 |
